VYNE Therapeutics Inc

VYNE Therapeutics has declared a one‑time cash dividend of about 16.5 million USD (estimated at 0.38 USD per share) in connection with its planned merger with Yarrow Bioscience. Eligible shareholders and warrant holders are those registered on 22 July 2026; payment to the transfer agent is scheduled for 23 July 2026. The payout is conditional on completion of the merger, expected around 24 July 2026, and on shareholder approval at an extraordinary general meeting on 16 July 2026. According to analysis, VYNE has more cash than debt, supporting the dividend’s funding, although the actual amount may differ from the estimate. » Más en de.investing.com

VYNE Therapeutics will merge with privately held Yarrow Bioscience; the transaction is intended to create a company focused on autoimmune thyroid diseases that will trade on NASDAQ under the ticker YARW. A consortium led by RTW Investments and OrbiMed Advisors has committed roughly $200 million in financing prior to closing. Yarrow’s lead program is the clinical candidate YB-101, designed to block thyroid-stimulating autoantibodies; a licensing agreement for YB-101 outside China has already been made with Shanghai Scizeng Medical Technology. The merger is expected to close in the second quarter of 2026. » Más en de.investing.com

VYNE Therapeutics announced that its phase 2b study of Repibresib gel for the treatment of non-segmental vitiligo failed to meet both the primary and a key secondary endpoint. Despite significant effects at the highest dose, the company plans to complete the extension phase of the study and seek an external partner for further development. Analysts responded by downgrading the stock, while the company's financial situation remains strained. » Más en de.investing.com